BioPharma Credit (BPCR) Competitors GBX 0.86 0.00 (0.00%) (As of 11/18/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendInsider Trades BPCR vs. NBMI, FWD, ANIC, CLC, ASIZ, MAVT, BRIG, CTNA, DRUM, and STMShould you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include NB Global Monthly Income Fund Ltd GBP (NBMI), Forward Partners Group (FWD), Agronomics (ANIC), Calculus VCT (CLC), Aberforth Split Level Income ZDP 2024 (ASIZ), Momentum Multi-Asset Value Trust (MAVT), BlackRock Income and Growth (BRIG), Catena Group (CTNA), Drumz (DRUM), and STM Group (STM). These companies are all part of the "asset management" industry. BioPharma Credit vs. NB Global Monthly Income Fund Ltd GBP Forward Partners Group Agronomics Calculus VCT Aberforth Split Level Income ZDP 2024 Momentum Multi-Asset Value Trust BlackRock Income and Growth Catena Group Drumz STM Group BioPharma Credit (LON:BPCR) and NB Global Monthly Income Fund Ltd GBP (LON:NBMI) are both small-cap financial services companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk. Does the media refer more to BPCR or NBMI? In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled NB Global Monthly Income Fund Ltd GBP'saverage media sentiment score. Company Overall Sentiment BioPharma Credit Neutral NB Global Monthly Income Fund Ltd GBP Neutral Do insiders & institutionals have more ownership in BPCR or NBMI? 41.5% of BioPharma Credit shares are owned by institutional investors. Comparatively, 44.3% of NB Global Monthly Income Fund Ltd GBP shares are owned by institutional investors. 6.2% of BioPharma Credit shares are owned by company insiders. Comparatively, 0.2% of NB Global Monthly Income Fund Ltd GBP shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, BPCR or NBMI? BioPharma Credit has higher revenue and earnings than NB Global Monthly Income Fund Ltd GBP. BioPharma Credit is trading at a lower price-to-earnings ratio than NB Global Monthly Income Fund Ltd GBP, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioPharma Credit£135.74M0.08£108.45M£0.0810.80NB Global Monthly Income Fund Ltd GBPN/AN/AN/A£0.17338.24 Is BPCR or NBMI more profitable? BioPharma Credit has a net margin of 79.90% compared to NB Global Monthly Income Fund Ltd GBP's net margin of 0.00%. BioPharma Credit's return on equity of 8.10% beat NB Global Monthly Income Fund Ltd GBP's return on equity.Company Net Margins Return on Equity Return on Assets BioPharma Credit79.90% 8.10% 4.98% NB Global Monthly Income Fund Ltd GBP N/A N/A N/A Does the MarketBeat Community believe in BPCR or NBMI? BioPharma Credit received 84 more outperform votes than NB Global Monthly Income Fund Ltd GBP when rated by MarketBeat users. CompanyUnderperformOutperformBioPharma CreditOutperform Votes8464.62% Underperform Votes4635.38% NB Global Monthly Income Fund Ltd GBPN/AN/A Is BPCR or NBMI a better dividend stock? BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 810.2%. NB Global Monthly Income Fund Ltd GBP pays an annual dividend of GBX 9 per share and has a dividend yield of 15.7%. BioPharma Credit pays out 8,750.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NB Global Monthly Income Fund Ltd GBP pays out 5,294.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. SummaryBioPharma Credit beats NB Global Monthly Income Fund Ltd GBP on 7 of the 11 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get BioPharma Credit News Delivered to You Automatically Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPCR vs. The Competition Export to ExcelMetricBioPharma CreditAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£10.37M£799.71M£3.30B£1.35BDividend Yield7.73%13.35%4.62%11.62%P/E Ratio10.80756.34433.621,581.27Price / Sales0.0813,644.302,912.86188,239.28Price / Cash1.1981.9048.6334.04Price / Book0.011.721.502.82Net Income£108.45M£58.77M£332.03M£129.01M7 Day Performance0.47%-0.83%6.14%3.68%1 Month Performance-1.59%0.58%0.84%2.33%1 Year Performance2.37%10.99%16.24%111.46% BioPharma Credit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPCRBioPharma CreditN/AGBX 0.86flatN/A+1.9%£10.37M£135.74M10.80N/ANBMINB Global Monthly Income Fund Ltd GBPN/AGBX 57.50+2.7%N/AN/A£41.02MN/A338.24N/AGap UpFWDForward Partners GroupN/AGBX 29.50flatN/AN/A£39.78M£-22,030,000.00-155.2615High Trading VolumeANICAgronomics2.0493 of 5 starsGBX 3.90flatN/A-59.1%£39.39M£10.94M470.00N/ACLCCalculus VCTN/AGBX 58flatN/AN/A£39.36M£1.53M5,800.00N/AASIZAberforth Split Level Income ZDP 2024N/AGBX 126.50flatN/AN/A£39.23M£821,000.00-45.18N/AMAVTMomentum Multi-Asset Value TrustN/AGBX 142.50+0.7%N/AN/A£38.97M£-8,390,000.00-459.68N/ABRIGBlackRock Income and GrowthN/AGBX 190-2.6%N/A+9.6%£37.62M£2.55M2,111.11N/ADividend IncreaseCTNACatena GroupN/AGBX 89-1.1%N/AN/A£36.86M£883,133.00-68.46133DRUMDrumzN/AGBX 8.75+16.7%N/AN/A£36.73M£56,000.00-875.00N/AGap UpHigh Trading VolumeSTMSTM GroupN/AGBX 61.50flatN/A+11.8%£35.53M£30.06M3,075.0048,300 Related Companies and Tools Related Companies NB Global Monthly Income Fund Ltd GBP Alternatives Forward Partners Group Alternatives Agronomics Alternatives Calculus VCT Alternatives Aberforth Split Level Income ZDP 2024 Alternatives Momentum Multi-Asset Value Trust Alternatives BlackRock Income and Growth Alternatives Catena Group Alternatives Drumz Alternatives STM Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:BPCR) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
